Decoy Therapeutics Files S-1 for Nasdaq IPO
Decoy Therapeutics Inc., a biotech focused on tumor microenvironment therapies, filed its S-1 registration statement with the SEC on October 7, 2026, initiating its Nasdaq IPO process. With no approved products and preclinical-to-Phase I transition status, the filing will emphasize pipeline progress, clinical trial budgeting, and three-year capital expenditure planning.
51CFO view：Early-stage biotechs demand CFOs who can build SEC-compliant 'no-revenue' financial models, rigorously apply ASC 730 R&D expense classification, and quantify burn rate/cash runway in MD&A. They must also design R&D cost accounting systems compliant with both FDA traceability and SEC disclosure rules.
Decoy Therapeutics Inc., a biotech focused on tumor microenvironment therapies, filed its S-1 registration statement with the SEC on October 7, 2026, initiating its Nasdaq IPO process. With no approved products and preclinical-to-Phase I transition status, the filing will emphasize pipeline progress, clinical trial budgeting, and three-year capital expenditure planning.
Source：SEC EDGAR · S-1 招股书备案